Primary Tumor Surgery for Patients with De Novo Stage IV Breast Cancer can Decrease Local Symptoms and Improve Quality of Life.
De novo stage IV breast cancer
Local symptoms
Primary tumor surgery
Quality of life
Survival
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
received:
17
09
2019
pubmed:
24
1
2020
medline:
29
12
2020
entrez:
24
1
2020
Statut:
ppublish
Résumé
It was unknown whether surgery for primary tumor would affect the occurrence of local symptoms caused by tumor progression in patients with de novo stage IV breast cancer (BC). Our work attempted to probe the effect of local resection on controlling local symptoms and improving the quality of life in de novo stage IV BC patients. Our study included patients presenting with de novo stage IV BC at the Cancer Hospital of the Chinese Academy of Medical Sciences from January 2008 to December 2014. In this study, we defined a new term called "local progress/recurrence of symptoms" (LPRS) to refer to the local problems caused by tumor progression/recurrence. All the patients were grouped into surgery and non-surgery groups. The characteristics of the two groups were analyzed by Chi square and Fisher's test. Univariate and multivariate Cox regression models were designed to evaluate independent prognostic factors. This study contained 177 patients. The follow-up deadline was April 1, 2019. The median follow-up time was 33 months (range 1-135 months). In included patients, 77 (43.5%) underwent surgery for primary tumors. Primary tumor surgery could reduce the occurrence of LPRS (relative risk/risk ratio (RR = 0.440; 95% CI 0.227-0.852; p = 0.015)) and patients without LPRS had longer OS (45 months vs 29 months, p < 0.001). In addition, patients who had only one symptom had better OS than those who had two or three symptoms (p = 0.0175). The quality of life in patients with de novo stage IV breast cancer can be improved by reducing the incidence of local symptoms through primary tumor surgery.
Sections du résumé
BACKGROUND
BACKGROUND
It was unknown whether surgery for primary tumor would affect the occurrence of local symptoms caused by tumor progression in patients with de novo stage IV breast cancer (BC). Our work attempted to probe the effect of local resection on controlling local symptoms and improving the quality of life in de novo stage IV BC patients.
METHODS
METHODS
Our study included patients presenting with de novo stage IV BC at the Cancer Hospital of the Chinese Academy of Medical Sciences from January 2008 to December 2014. In this study, we defined a new term called "local progress/recurrence of symptoms" (LPRS) to refer to the local problems caused by tumor progression/recurrence. All the patients were grouped into surgery and non-surgery groups. The characteristics of the two groups were analyzed by Chi square and Fisher's test. Univariate and multivariate Cox regression models were designed to evaluate independent prognostic factors.
RESULTS
RESULTS
This study contained 177 patients. The follow-up deadline was April 1, 2019. The median follow-up time was 33 months (range 1-135 months). In included patients, 77 (43.5%) underwent surgery for primary tumors. Primary tumor surgery could reduce the occurrence of LPRS (relative risk/risk ratio (RR = 0.440; 95% CI 0.227-0.852; p = 0.015)) and patients without LPRS had longer OS (45 months vs 29 months, p < 0.001). In addition, patients who had only one symptom had better OS than those who had two or three symptoms (p = 0.0175).
CONCLUSIONS
CONCLUSIONS
The quality of life in patients with de novo stage IV breast cancer can be improved by reducing the incidence of local symptoms through primary tumor surgery.
Identifiants
pubmed: 31970572
doi: 10.1245/s10434-019-08092-2
pii: 10.1245/s10434-019-08092-2
pmc: PMC7060161
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1025-1033Subventions
Organisme : National Key Research and Development Project
ID : 2018YFC0115204
Organisme : National Natural Science Foundation of China
ID : NO. 81472753
Organisme : National Natural Science Foundation of China
ID : NO.81672634
Organisme : Capital Health Development Research Project
ID : 2018-2-4023
Références
Linos E, Spanos D, Rosner BA, et al. Effects of reproductive and demographic changes on breast cancer incidence in China: a modeling analysis. J Natl Cancer Inst. 2008;100:1352–60.
doi: 10.1093/jnci/djn305
National Comprehensive Cancer Network (NCCN): Clinical practice guidelines in oncology: Breast Cancer, version 1; 2016. www.nccn.org/professionals/physician_gls/pdf/breast.pdf .
Malmgren JA, Mayer M, Atwood MK, et al. Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat. 2018;167(2):579–90.
doi: 10.1007/s10549-017-4529-5
Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 2015;16:1380–8.
doi: 10.1016/S1470-2045(15)00135-7
Soran A, Ozmen V, Ozbas S, et al. A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: Turkish study (protocol MF07-01). J Clin Oncol. 2016;34(suppl):abstr 1005.
doi: 10.1200/JCO.2016.34.15_suppl.1005
Fitzal F, Bjelic-Radisic V, Knauer M, et al. Impact of breast surgery in primary metastasized breast cancer: outcomes of the prospective randomized phase III ABCSG-28 POSYTIVE trial. Ann Surg. 2019;269(6):1163–9.
doi: 10.1097/SLA.0000000000002771
Arciero C, Liu Y, Gillespie T, et al. Surgery and survival in patients with stage IV breast cancer. Breast J. 2019. https://doi.org/10.1111/tbj.13296 .
doi: 10.1111/tbj.13296
pubmed: 31448512
Thomas A, Khan SA, Chrischilles EA, et al. Initial surgery and survival in stage IV breast cancer in the United States, 1988–2011. JAMA Surg. 2016;151:424–31.
doi: 10.1001/jamasurg.2015.4539
Badwe R, Hawaldar R, Nair N, et al. Locoregional treatment versus no treatment of primary tumor in metastatic breast cancer: an open-label randomized controlled trial. Lancet Oncol. 2015;16:1380–8.
doi: 10.1016/S1470-2045(15)00135-7
Ruiterkamp J, Ernst MF. The role of surgery in metastatic breast cancer. Eur J Cancer. 2011;47(Suppl3):S6–22.
doi: 10.1016/S0959-8049(11)70142-3
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.
doi: 10.1245/s10434-010-0985-4
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.
doi: 10.1093/annonc/mdt303
Khan SA, DesJardin ESM. Readdressing the role of surgery of the primary tumor in de novo stage IV breast cancer. Cancer Treat Res. 2018;173:73–88.
doi: 10.1007/978-3-319-70197-4_6
Ruiterkamp J, Voogd AC, Bosscha K, et al. Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature. Breast Cancer Res Treat. 2010;120:9–16.
doi: 10.1007/s10549-009-0670-0
Xiong Z, Deng G, Wang J, et al. Could local surgery improve survival in de novo stage IV breast cancer? BMC Cancer. 2018;18(1):885.
doi: 10.1186/s12885-018-4767-x
Bafford AC, Burstein HJ, Barkley CR, et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009;115:7–12.
doi: 10.1007/s10549-008-0101-7
Wang K, Shi Y, Li ZY, et al. Metastatic pattern discriminates survival benefit of primary surgery for de novo stage IV breast cancer: a real-world observational study. Eur J Surg Oncol. 2019;S0748–7983(19):30283–5.
de Mello Ramirez Medina J, de Araujo Trugilho I, Mendes GNB, et al. Advanced clinical stage at diagnosis of breast cancer is associated with poorer health-related quality of life: a cross-sectional study. Eur J Breast Health. 2019;15(1):26–31.
doi: 10.5152/ejbh.2018.4297
Staren ED, Gupta D, Braun DP, et al. The prognostic role of quality of life assessment in breast cancer. Breast J. 2011;17(6):571–8.
doi: 10.1111/j.1524-4741.2011.01151.x
Coates AS, Hürny C, Peterson HF, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol. 2000;18(22):3768–74.
doi: 10.1200/JCO.2000.18.22.3768